Treatment of Facial Basal Cell Carcinoma: A Review

Links shared publicly online about this topic.

333
total visits

Treatment of Facial Basal Cell Carcinoma: A Review

Basal cell carcinomas (BCCs) are locally destructive malignancies of the skin. They are the most common type of cancer in the western world. The lifetime incidence may be up to 39%. UV exposure is the most common risk factor. The majority of these tumours occur on the head and neck. Despite BCCs being relatively indolent the high incidence means that their treatment now contributes a significant and increasing workload for the health service. A good understanding of the options available is impo

View full resource at hindawi.com

Tags: Skin, Cancer, Malignancy, Skin Cancer, Basal Cell Carcinoma, Healthy Living

Most Recently Shared on April 28, 2011 at 7:04 am By:

Skin Cancer OW

Treatment of Facial Basal Cell Carcinoma: A Review: Basal cell carcinomas (BCCs) are locally destructive maligna... http://bit.ly/m7O5wD

12 months ago...

Retweet

Favorite

Vismodegib, Investigational Drug for Basal Cell Carcinoma, Receives Priority Review Status from the FDA | Skin & Aging

skinandaging.com — “Vismodegib, Investigational Drug for Basal Cell Carcinoma, Receives Priority Review Status from the FDA | Skin & Aging” View full resource at skinandaging.com

Most Recently Shared on November 11, 2011 at 6:52 pm By:

Skin & Aging Dermatology and Medical Journal

Vismodegib, an investigational drug for the treatment of advanced basal cell carcinoma, has been granted Priority... http://t.co/seXufeuH

5 months ago...

Retweet

Favorite

FDA to review a Genentech skin-cancer treatment - MarketWatch

marketwatch.com — “TEL AVIV (MarketWatch) -- Roche Holding AG's Genentech subsidiary said on Wednesday that the U.S. Food and Drug Administration agreed to review vismodegib, a proposed treatment taken by mouth for adults who have advanced basal-cell carcinoma and aren't able to undergo surgery. The new-drug application was granted priority-review status and the FDA set a March 8 deadline for action on the drug. The disease is the most common skin cancer and is usually curable with surgery, the South San F” View full resource at marketwatch.com